Email Contact Phone Company Visit Website

Location Office

Kungsgatan 36
Stockholm
SE

NASDAQ OMX New York Head Office

One Liberty Plaza
New York
NY
US

NASDAQ OMX Stockholm Office

Tullvaktsvägen 15
Stockholm
SE

NASDAQ OMX Rockville Office

805 King Farm Boulevard 1st and 2nd floor
Rockville
MD
US

NASDAQ OMX London Office

Woolgate Exchange, 25 Basinghall Street, City of London
London
GB

NASDAQ OMX New York Office

Marketsite 4 Times Square
New York
NY
US

NASDAQ OMX Hong Kong Office

Room 1207-8, 12/F Man Yee Building 68 Des Voeux Road Central Hong Kong
Hong Kong
HK

NASDAQ OMX Singapore Office

20 Collyer Quay, #17-01
Singapore
SG

NASDAQ OMX Chicago Office

One North Wacker Drive Suite 3600
Chicago
IL
US

NASDAQ OMX Belgium Office

Avenue de Cortenbergh 116
Brussels
BE

NASDAQ OMX Dubai Office

Dubai World Trade Centre Sheikh Zayed Road
Dubai
AE

NASDAQ OMX Tokyo Office

1F, Kojimachi Square Building Nibancho, 3 Chiyoda-ku, Tokyo
Tokyo
JP

NASDAQ OMX Boston Office

100 Franklin St
Boston
MA
US

Location Office

Level 17-19, 110 Bishopsgate
London
GB

Telephone

212 231 5018

Contact

Todd A Swearingen
[email protected]
Back to all NASDAQ OMX announcements

Nasdaq Welcomes DBV Technologies (Nasdaq: DBVT) to The Nasdaq Stock Market

Nasdaq (Nasdaq:NDAQ) announced that trading of DBV Technologies (Nasdaq:DBVT), a clinical-stage specialty biopharmaceutical company, commenced on The Nasdaq Stock Market on October 22, 2014.

Headquartered in Bagneux, France, DBV Technologies is a biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®. The company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. DBV Technologies is focusing on severe food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies was incorporated in 2002.

"As allergies become increasingly prevalent as a major health issue, DBV Technologies continues to evolve and innovate in this field," said Adam Kostyál, Senior Vice President, Listing Services, Nasdaq. "We are proud to have DBV Technologies listed on The Nasdaq Stock Market."

By listing with Nasdaq, DBV Technologies joins many of the world's largest and most revolutionary companies. Nasdaq has been the exchange of choice to 93 percent of healthcare companies listed in the U.S. markets.